Findings from a clinical trial led by Rockefeller University scientists as reported by journal Nature highlight anti-HIV antibodies as a novel treatment option; one that wouldn’t rely on vigilant daily dosing and could potentially reduce the body’s reservoir of HIV, which conventional antiretroviral drugs cannot do.
Read the full article here